PDX Research Hub
Pharmacodiagnostics — bringing the lab to the pharmacy. One question, studied across five areas: can pharmacists generate, interpret, and act on diagnostic data right where the medication decision happens?
Test Explorer
test · category · machine · what it tells youPick a test to see what it measures, what a result reveals, and whether it can screen.
Learn
No science background needed — pick any question; each answer stands on its own.
What is a lab test — and what is a panel?
A test measures one substance — an analyte (the specific thing being measured: glucose, sodium, a particular protein). One analyte, one result. A panel isn't a different kind of measurement — it's a billing bundle of individual tests run together from one blood draw. You stick the patient once; the analyzer reads many analytes off that single sample.
What machines run these tests — and what does “point-of-care” mean?
Point-of-care (POC) is not a machine — it’s a setting. It means the test is run right where the patient is, with a result in minutes, instead of shipping the sample to a central lab. POC devices are small, often handheld, and usually CLIA-waived — which is exactly why they are the realistic starting point for a pharmacy.
The machine families are a separate question — the kind of instrument that does the chemistry: chemistry, hematology, immunoassay, coagulation, and molecular analyzers. The same test can live in either world: A1c can run on a benchtop chemistry analyzer in a central lab, or on a small waived POC device in a pharmacy — same test, different setting.
Specific devices, costs, and throughput fill in as the Machines section is built.
How do you pay for a lab machine?
Mostly, you don’t buy it outright. The common model is reagent rental / placement: the vendor places the instrument at little or no upfront cost, and you commit to buying its per-test reagents — the cartridges, discs, or strips. Service, warranty, installation, and operator training are usually bundled into that agreement. A few examples make it concrete: the Afinion 2 is often placed for $0 against a reagent commitment, and the Sofia 2 is typically leased.
The alternatives are a fixed-monthly lease, or an outright purchase (handhelds run a few hundred dollars; benchtops, low-to-mid thousands; high-end molecular boxes far more). Because vendors quote against your projected test volume, public sticker prices barely exist — the real figures surface on the refurbished and secondary market, which is where the per-device costs in the Machines section come from.
What is CLIA, and why does it decide so much?
CLIA (the federal lab law) sorts every test into a complexity category: Waived, Moderate, or High. The real jump isn't evenly spaced — it's the wall between Waived and everything above. Below the wall you just follow instructions; above it you are legally a laboratory, with a director, quality control, proficiency testing, and inspections.
One more thing that trips people up: complexity is assigned to a test on a specific device, not to the machine. The FDA rates each device’s version of a test, so the “same” test can be waived on a simple handheld and moderate on a big analyzer. A device gets called “waived” as shorthand when every test on its menu is waived — and that’s no accident: makers design point-of-care boxes to clear the waived bar, because that’s what lets a pharmacy run them on just a Certificate of Waiver. Waived still means a permit and trained operators — the lightest tier, not no rules. (And not every device clears it: the Afinion is waived for its HbA1c but moderate for its ACR cartridge — one box, two ratings.)
Who is allowed to run a test — and what's a permit?
Permits aren't per-test — they're per-site, and the tier is set by the single highest-complexity test on your menu. They stack across three levels of government, and you climb all three at once. A “permit” is the certificate that says your site is allowed to run that tier of testing.
How does a test actually get paid for?
Every insurance claim needs two codes that must agree. CPT (from the AMA) says what you did — e.g., 80053 for a metabolic panel. ICD-10 says why — the diagnosis that justifies it. If the “why” doesn't support the “what,” the claim is denied. That match is called medical necessity, and it's the hinge the whole financial model turns on.
The same procedure can be free or cost-shared depending only on the “why.” An HbA1c (CPT 83036) billed with diabetes screening (ICD-10 Z13.1) is a covered, no-cost-share preventive test. The same 83036, billed to work up a patient’s symptoms, is diagnostic — and the patient pays a share.
What makes a test “preventive”?
Some screenings must be covered with no copay. Under the ACA, services the USPSTF grades A or B are required to be covered in full by most plans. The trick: the same test is “preventive” (no cost-share, billed with a screening code) or “diagnostic” (cost-shared) depending on why it's run. Pharmacists can already order many preventive tests — PDX is about doing it where the patient already is. That's why every test record carries a clinical screening-capable flag, including a yellow “maybe” for the frontier we want to expand.
The three payer lanes reach that no-cost-share point by different routes. Commercial plans follow the ACA mandate directly. Medicare carries its own list of covered preventive services, which overlaps heavily with the USPSTF grades. Medi-Cal (California's Medicaid) covers the A/B set as well. What none of this settles is the per-plan detail — frequency limits, prior authorization, and whether a pharmacist can bill as the performing provider.
For PDX the takeaway is blunt: the clinical case and the coverage case are the same case. The preventive screenings a pharmacist can perform are largely already covered — the open question is whether a pharmacist can bill for performing them.
Machines
Pick a category to see its devices, then tap any device for its own page — manufacturer, sample, speed, cost, and more. The five families are the kinds of analyzer, Core lab is the big hospital and reference-lab machines, and Cutting Edge is the frontier.
Manufacturers
The companies behind the devices. Tap any maker for a short profile and links to its analyzers.
Codes
Two codes per claim — what was done (CPT) and why (ICD-10). They have to agree to get paid, and the “why” is what makes a screening free.
Checklists
What it actually takes to run lab tests in a pharmacy. Two players need credentials. Tap any credential to open its page, or use the apply link to jump straight to its application.
Certificates
The five federal CLIA certificate types, lowest to highest. The one you hold is set by the highest-complexity test on your menu. Tap any to open its page.
Scope of Practice
What a California pharmacist is legally allowed to do today — and where the lines are that would need protocol, supervision, or a change in the law.
Education
What a pharmacist must learn for the model, against what the PharmD already covers.
Coverage
Who pays, and under what rules.
This section is still being researched. The coverage picture — per-plan rules, prior authorization and frequency limits, and the specifics for Medi-Cal, Medicare, and commercial plans — needs to be worked out before it earns a place here. The underlying concept (why the same test can be free or cost-shared) lives in Learn for now.
Industry & Economics
Before asking whether a pharmacy lab can make money, it helps to look at the companies that already do this at the largest scale — Quest and Labcorp. Their numbers show what's possible, what isn't, and where a small pharmacy actually has an edge.
The U.S. lab industry is dominated by two names: Quest Diagnostics and Labcorp. They are enormous. In 2025 Quest took in about $11 billion. Labcorp, which also runs a separate drug-development business, is larger still — its lab-testing arm alone is around $10 billion a year. When you send a sample off to “the lab,” it usually means one of these two.
Here's the surprising part. For all that size, they keep only a small slice. Out of every dollar of testing revenue, roughly two-thirds goes straight back out as the cost of running the test — reagents, instruments, couriers, technicians. After everything else — buildings, billing, administration — the profit they actually keep lands in the single digits to low teens as a share of revenue. Quest does $11 billion in sales and keeps on the order of a billion. Lab testing is a thin-margin, high-volume business; it is not a place where any one test makes you rich.
This is the number that matters for PDX. These companies are paid per test largely off the same public price list — Medicare's clinical-lab fee schedule — that anchors our own model. A routine test like an A1c or a lipid panel pays only about $10 to $15. And by Quest's own reporting, the revenue it earns per order barely changes from one year to the next; what grows is the number of orders. The giants don't win by charging more per test — they win by doing more tests. The price is essentially fixed and low for everyone, a pharmacy included.
If the price is the same for everyone, why are Quest and Labcorp profitable at all? Scale. A national lab runs millions of samples through highly automated machines, with couriers consolidating thousands of specimens onto efficient routes and reagents bought by the truckload. That efficiency is the whole game, and it only exists at massive volume. A pharmacy running a few dozen patients a week cannot manufacture it — so it cannot expect the giants' margins. The financial model reflects this honestly: at low volume the numbers are thin, and they can even be negative.
A pharmacy lab will never beat Quest on cost per test — and that's the wrong contest. The edge is everywhere the giants are weak. With a national lab, the patient gives a sample and waits days for a result that goes to a doctor somewhere else. In a pharmacy, the test happens where the patient already is, the result is ready in minutes, and the pharmacist can act on it and hand it straight to the prescriber — in a single visit. That convenience, that relationship, and that role as a fast, reliable data feed to the prescriber are things scale can't buy. PDX doesn't compete with the giants on their turf; it wins on the turf they can't reach.
The financial model turns all of this into numbers you can change — your payer mix, your test menu, your patient volume — and shows where a specific pharmacy lands. Run your own numbers →
Figures from Quest Diagnostics' and Labcorp's full-year 2025 results (reported February 2026) and the U.S. Medicare Clinical Laboratory Fee Schedule. Per-test dollar figures are approximate, for orientation.
Case Studies
The evidence that pharmacist-led testing and care improve outcomes. Each entry: the study, its key findings, and a link to the source.
A 13-month pilot at two Kaiser Permanente outpatient pharmacies let pharmacists order HbA1c labs and run extended adherence consultations for diabetes patients who were nonadherent to their oral medications (HbA1c ≥ 8% or missing their annual test), measured against usual provider-ordered care.
- Of 793 HbA1c orders, 87 were pharmacist-initiated and 706 came through usual care.
- Far more pharmacist-group patients reached an HbA1c below 8% — 34.9% vs 12.2% — a statistically significant gap.
- The pharmacist group's average HbA1c fell from 9.47% to 8.68% (a significant 0.79-point drop); the usual-care group barely moved (9.70% to 9.43%, not significant).
- Lab completion was higher in the pharmacist group (49.4% vs 39.5%), though that difference was not significant.
- The service added about 5 minutes per encounter and an hour of training, but did not increase patient wait times or reduce pharmacy productivity.
This is direct evidence under California SB 493 — the same legal basis PDX builds on — that pharmacist-linked testing can improve outcomes without disrupting pharmacy operations. It also names PDX's two hardest barriers honestly: there is no clear reimbursement model for pharmacist lab ordering, and the pharmacy needs access to the medical record (Kaiser had an integrated EMR; most community pharmacies do not).
Read with care: the pharmacist group was small, many patients in both groups never completed their labs, and the average post-HbA1c was still ≥ 8% — encouraging, not conclusive.
View the study →Proposal
Where everything converges — the integrated business plan and pilot.
About PDX
PDX puts diagnostic testing where the prescription happens — a pharmacist orders the test, reads it, and acts on it in one visit. It is an approved Chapman University School of Pharmacy elective, researched here across five areas: clinical, regulatory, operations, education, and finance.
PDX is studied as a chain: each area hands the next a narrower model. They are lenses, not boxes — a single thing (a permit, say) is legal, financial, and educational at once. Each names the hub sections it feeds.
- Pick the strongest starting service line and patient group.
- Define the pharmacist action on a result, and the referral triggers.
- Choose the first outcomes a pilot would measure.
- Separate what pharmacists can do today from what needs a protocol or a law change.
- Map the CLIA complexity wall for each test.
- Identify the permits, personnel licensure, and accreditation the site would need.
- Define the minimum viable setup: test menu, devices, workflow, QC.
- Tie each test to its machine and CLIA complexity.
- Find the operational limits on speed, scale, and staffing.
- Compare the model's required skills against today's PharmD.
- Name the training gaps (phlebotomy, QC, interpretation).
- Propose the minimum added training and how it fits at Chapman.
- Find the revenue pathways: codes, coverage, who pays.
- Map the costs: machines, staffing, permits.
- Build the break-even case that lands in the Proposal.